Published in JAMA on January 03, 2007
Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI) | NCT00091637
Ischemia and reperfusion--from mechanism to translation. Nat Med (2011) 6.64
The immune system and cardiac repair. Pharmacol Res (2008) 3.42
Complement-targeted therapeutics. Nat Biotechnol (2007) 3.24
Regulation of the inflammatory response in cardiac repair. Circ Res (2012) 3.21
Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest (2013) 2.83
Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol (2010) 2.52
Macrophage roles following myocardial infarction. Int J Cardiol (2008) 2.14
The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol (2014) 1.99
Cardiac cell repair therapy: a clinical perspective. Mayo Clin Proc (2009) 1.62
Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol (2016) 1.46
Salivating for knowledge: potential pharmacological agents in tick saliva. PLoS Med (2008) 1.46
Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. CMAJ (2012) 1.45
Pexelizumab does not "complement" percutaneous coronary intervention in patients with ST-elevation myocardial infarction. JAMA (2007) 1.45
B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med (2013) 1.43
Addressing the challenges of a cross-national investigation: lessons from the Pittsburgh-Pisa study of treatment-relevant phenotypes of unipolar depression. Clin Trials (2008) 1.36
The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. Circ Res (2016) 1.27
Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J Clin Invest (2011) 1.24
Recent developments in low molecular weight complement inhibitors. Mol Immunol (2009) 1.23
Targeting inflammatory pathways in myocardial infarction. Eur J Clin Invest (2013) 1.10
The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities. J Cardiovasc Pharmacol (2014) 1.08
Role of the complement components C5 and C3a in a mouse model of myocardial ischemia and reperfusion injury. Ger Med Sci (2010) 1.05
Cardioprotection and myocardial reperfusion: pitfalls to clinical application. Circ Res (2013) 1.03
Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando) (2009) 1.03
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J (2009) 1.01
Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. Am Heart J (2010) 1.00
Myocardial salvage in acute myocardial infarction--challenges in clinical translation. J Mol Cell Cardiol (2011) 0.98
Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights. Circ Cardiovasc Qual Outcomes (2012) 0.97
Stromal derived factor 1α: a chemokine that delivers a two-pronged defence of the myocardium. Pharmacol Ther (2014) 0.95
Complement activation and prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care (2012) 0.91
Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br J Pharmacol (2014) 0.90
The inflammatory response and cardiac repair after myocardial infarction. Korean Circ J (2009) 0.89
Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges. Transl Res (2015) 0.87
Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res (2014) 0.84
Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model. BMC Cardiovasc Disord (2010) 0.84
Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin. EBioMedicine (2016) 0.83
Targeting the chemokines in cardiac repair. Curr Pharm Des (2014) 0.82
Mannan-binding lectin in cardiovascular disease. Biomed Res Int (2014) 0.81
Present and future of secondary prevention after an acute coronary syndrome. EPMA J (2011) 0.80
The complement system and adverse pregnancy outcomes. Mol Immunol (2015) 0.80
Integrins and integrin-related proteins in cardiac fibrosis. J Mol Cell Cardiol (2015) 0.80
Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial. J Neuroinflammation (2015) 0.80
No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J (2016) 0.79
Nanoparticle-Mediated Delivery of Irbesartan Induces Cardioprotection from Myocardial Ischemia-Reperfusion Injury by Antagonizing Monocyte-Mediated Inflammation. Sci Rep (2016) 0.78
Conditioning the heart to prevent myocardial reperfusion injury during PPCI. Eur Heart J Acute Cardiovasc Care (2012) 0.78
Platelets and the complement cascade in atherosclerosis. Front Physiol (2015) 0.77
Anticomplement therapy. Biologics (2008) 0.76
The Fifth Domain of Beta 2 Glycoprotein I Protects from Natural IgM Mediated Cardiac Ischaemia Reperfusion Injury. PLoS One (2016) 0.76
BMP Antagonist Gremlin 2 Limits Inflammation After Myocardial Infarction. Circ Res (2016) 0.76
Association between endogenous complement inhibitor and myocardial salvage in patients with myocardial infarction. Eur Heart J Acute Cardiovasc Care (2013) 0.76
Prognostic value of coronary CT angiography in diabetic patients: a 5-year follow up study. Int J Cardiovasc Imaging (2015) 0.76
Hotline sessions of the 30th European Congress of Cardiology. Eur Heart J (2009) 0.75
High Killips Class as a Predictor of New-onset Atrial Fibrillation Following Acute Myocardial Infarction: Systematic Review and Meta-analysis. Chin Med J (Engl) (2015) 0.75
Optimal Duration of Coronary Ligation and Reperfusion for Reperfusion Injury Study in a Rat Model. Acta Cardiol Sin (2016) 0.75
Serious infection after acute myocardial infarction: incidence, clinical features, and outcomes. JACC Cardiovasc Interv (2012) 0.75
Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function. Basic Res Cardiol (2017) 0.75
Activation of complement factor B contributes to murine and human myocardial ischemia/reperfusion injury. PLoS One (2017) 0.75
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 18.96
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Universal definition of myocardial infarction. Circulation (2007) 11.69
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14
Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet (2006) 7.33
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94
A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J (2003) 6.88
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86
Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet (2009) 6.83
The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Diagnostic accuracy of noninvasive coronary angiography using 64-slice spiral computed tomography. J Am Coll Cardiol (2005) 6.07
Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA (2007) 6.06
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74
Sinus of Valsalva aneurysms--47 years of a single center experience and systematic overview of published reports. Am J Cardiol (2007) 5.71
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg (2012) 5.49
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2003) 4.70
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation (2003) 4.43
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. J Am Coll Cardiol (2007) 3.83
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2008) 3.70
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62
The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J (2006) 3.62
Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation (2004) 3.56
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA (2005) 3.54
A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol (2002) 3.52
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA (2007) 3.48
Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J (2004) 3.45
Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med (2003) 3.43
Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation (2009) 3.18
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J (2006) 3.14
Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J (2005) 3.09
West African Ebola epidemic after one year--slowing but not yet under control. N Engl J Med (2014) 2.96
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J (2012) 2.94
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90
Outcomes following transcatheter aortic valve replacement in the United States. JAMA (2013) 2.88
Emergency department bypass for ST-Segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline program. Circulation (2013) 2.85
Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J (2005) 2.83
Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). Am J Cardiol (2002) 2.82
Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol (2009) 2.82
Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med (2004) 2.80
Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet (2009) 2.79
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation (2005) 2.78